Journal article

Role of anti-HBs in functional cure of HBeAg plus chronic hepatitis B patients infected with HBV genotype A

Hui Xu, Stephen Locarnini, Darren Wong, Rachel Hammond, Danni Colledge, Sally Soppe, Thao Huynh, Tim Shaw, Alexander J Thompson, Peter A Revill, P Mark Hogarth, Bruce D Wines, Renae Walsh, Nadia Warner



BACKGROUND & AIMS: HBsAg-specific antibody responses are difficult to detect during chronic hepatitis B infection (CHB) and are often overlooked. The aim of this study was to examine whether anti-HBs may be involved in functional cure (FC) by profiling anti-HBs responses in patients with CHB using a panel of specific assays. METHODS: Longitudinal serum samples were obtained from 25 patients with CHB who were infected with HBV genotype A and were undergoing nucleos(t)ide analogue (NA) treatment: 14 achieved FC while 11 remained infected (non-FC). Anti-HBs immune complexes (HBsAg-IC), FcγRIIIa dimer binding, epitope specificity and neutralisation efficacy were measured. RESULTS: HBsAg-IC peaks..

View full abstract


Awarded by National Health and Medical Research Council

Funding Acknowledgements

Gilead Sciences funded and conducted the original clinical trial, including the collection and storage of serum samples. Gilead Sciences were not involved in the experimental design, analysis, interpretation, or the decision to submit for publication, but kindly provided clinical materials. This study is partly supported by grants from the National Health and Medical Research Council (NHMRC -GNT1127538) and from The Australian Centre for HIV and Hepatitis Virology Research (ACH<SUP>2</SUP>).